QIDP Drug Update – Part 1: An Updated Who Is Who

It is time for a new look at the field of QIDP drugs. Today we are providing an updated searchable database which now has 57 entries.

(Status: 10/18/16)[table id=24 /]

Despite best efforts to provide accurate information, errors may have crept in. Please let us know if you detect mistakes. We will make corrections or post an update based on your feedback. Supporting evidence would be appreciated.

Some information is notoriously hard to come by. Is a certain drug after months or a year of inactivity still in development? When a compound fails to show up on a company’s pipeline we assume it has died even if there is no ‘official’ announcements of its demise, keeping in mind that lack of development for prolonged periods of time is not all that unusual.

There are plenty of examples of ‘sleeper’ programs that suddenly became active again, for instance after a pause due to outlicensing efforts when new sponsors have to get up to speed. Clearly, such long hibernation phases make it difficult to distinguish death from suspended animation and from other causes as may exist.

Development “Phase” designation is a dynamic property in the quick-paced world of QIDP drugs. Progress is often – but not always – faster than in standard anti-infective drug development; phases can be compressed or even skipped entirely.

Companies sometimes refer to their asset as ‘Phase 2 ready’ or indicate that an SPA has been agreed to with FDA – a sure sign that Phase 3 could start any time. Hence, Phase assignments may be outdated quickly; the attached table is no more than a snapshot in time.

Further analyses about the “State of QIDP drugs” will be the topic of an upcoming blog.

---